US FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals
The emergency use authorizations for Pfizer-BioNTech and Moderna Covid-19 vaccines have been amended to allow for use of a third dose in solid organ transplant recipients or those diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
Source:
US Food and Drug Administration
SPS commentary:
The authorizations have been amended to allow for an additional, or third, dose to be administered at least 28 days following the two-dose regimen of the same vaccine in the stated population. Following a review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines.